A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin

被引:6
作者
Adachi, Kai [1 ]
Okuwaki, Kosuke [1 ]
Nishiyama, Ryo [2 ]
Kida, Mitsuhiro [1 ]
Imaizumi, Hiroshi [1 ]
Iwai, Tomohisa [1 ]
Yamauchi, Hiroshi [1 ]
Kaneko, Toru [1 ]
Hasegawa, Rikiya [1 ]
Miyata, Eiji [1 ]
Kumamoto, Yusuke [2 ]
Koizumi, Wasaburo [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Gastroenterol, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520375, Japan
[2] Kitasato Univ, Sch Med, Dept Surg, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520375, Japan
关键词
Biliary tract cancer; Chemotherapy; Conversion surgery; Pathological complete response; BILIARY-TRACT CANCER; NAIVE JAPANESE PATIENTS; NAB-PACLITAXEL; PANCREATIC-CANCER; PLUS GEMCITABINE; PHASE I/II; CHEMOTHERAPY; COMBINATION; MULTICENTER; FOLFIRINOX;
D O I
10.1007/s12328-019-00972-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The patient was a 69-year-old female with a chief complaint of yellow staining of her urine. A detailed physical examination and laboratory tests were carried out, and as a result, her condition was diagnosed as unresectable advanced extrahepatic cholangiocarcinoma with liver metastases. Chemotherapy using gemcitabine + cisplatin was initiated, and computed tomography after six cycles revealed that the liver metastases had disappeared, and that a partial response was achieved in the primary tumor. After tan cycles, a pylorus-preserving pancreaticoduodenectomy was performed as conversion surgery, and as a result, a pathological complete response was achieved in the primary tumor. After the primary lesion was resected, we were able to start an adjuvant chemotherapy immediately. Approximately 19 months have passed since the surgery, and the patient is currently alive and recurrence-free. If an improvement of the outcomes of chemotherapy in unresectable advanced biliary tract carcinomas is achieved in the future, there could be an increase in the number of treatment-responsive cases like the one reported in this study. Accumulating a large number of cases successfully treated by conversion surgery, and conducting a detailed analysis of the postoperative course, may help design adequate treatment strategies.
引用
收藏
页码:466 / 472
页数:7
相关论文
共 23 条
  • [1] Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
    Arai, Yasuhito
    Totoki, Yasushi
    Hosoda, Fumie
    Shirota, Tomoki
    Hama, Natsuko
    Nakamura, Hiromi
    Ojima, Hidenori
    Furuta, Koh
    Shimada, Kazuaki
    Okusaka, Takuji
    Kosuge, Tomoo
    Shibata, Tatsuhiro
    [J]. HEPATOLOGY, 2014, 59 (04) : 1427 - 1434
  • [2] Using 18F-Fluorodeoxyglucose Positron Emission Tomography to Monitor Clinical Outcomes in Patients Treated With Neoadjuvant Chemo-Radiotherapy for Locally Advanced Pancreatic Cancer
    Choi, Minsig
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Lawhorn-Crews, Jawana M.
    Zalupski, Mark M.
    Shields, Anthony F.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (03): : 257 - 261
  • [3] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [4] EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335
  • [5] Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery
    Kato, Atsushi
    Shimizu, Hiroaki
    Ohtsuka, Masayuki
    Yoshitomi, Hideyuki
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Nakadai, Eri
    Kishimoto, Takashi
    Nakatani, Yukio
    Yoshidome, Hiroyuki
    Miyazaki, Masaru
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S1093 - S1099
  • [6] Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
    Lee, Jeeyun
    Park, Se Hoon
    Chang, Heung-Moon
    Kim, Jun Suk
    Choi, Hye Jin
    Lee, Myung Ah
    Jang, Joung Soon
    Jeung, Hei Cheul
    Kang, Jung Hun
    Lee, Hyun Woo
    Shin, Dong Bok
    Kang, Hye Jin
    Sun, Jong-Mu
    Park, Joon Oh
    Park, Young Suk
    Kang, Won Ki
    Lim, Ho Yeong
    [J]. LANCET ONCOLOGY, 2012, 13 (02) : 181 - 188
  • [7] A Case of Common Bile Duct Cancer That Completely Responded to Combination Chemotherapy of Gemcitabine and TS-1
    Lim, Joo Hyun
    Ryu, Ji Kon
    Choi, Yoon Jin
    Kwon, Jieun
    Kim, Ji Yeon
    Lee, Yun Bin
    Kim, Jae Hwan
    Yoon, Won Jae
    Kim, Yong Tae
    Yoon, Yong Bum
    [J]. GUT AND LIVER, 2013, 7 (03) : 371 - 376
  • [8] Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan
    Miyakawa, Shuichi
    Ishihara, Shin
    Horiguchi, Akihiko
    Takada, Tadahiro
    Miyazaki, Masaru
    Nagakawa, Takukazu
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2009, 16 (01): : 1 - 7
  • [9] Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)
    Mizusawa, Junki
    Morizane, Chigusa
    Okusaka, Takuji
    Katayama, Hiroshi
    Ishii, Hiroshi
    Fukuda, Haruhiko
    Furuse, Junji
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (04) : 385 - 388
  • [10] Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805)
    Morizane, Chigusa
    Okusaka, Takuji
    Mizusawa, Junki
    Takashima, Atsuo
    Ueno, Makoto
    Ikeda, Masafumi
    Hamamoto, Yasuo
    Ishii, Hiroshi
    Boku, Narikazu
    Furuse, Junji
    [J]. CANCER SCIENCE, 2013, 104 (09): : 1211 - 1216